ORKA Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. (ORKA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $1.4M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| BALL KRISTINE M 6 fills | Director | Sell 10b5-1 | 18,000 | $104.93 | $1.9M | 16,804 −51.7% of holding | |
| Agarwal Arjun 6 fills | Senior Vice President, Finance | Sell 10b5-1 | 10,000 | $104.97 | $1.0M | 23,719 −29.7% of holding | |
| Klein Lawrence Otto 5 fills | Chief Executive Officer | Sell 10b5-1 | 25,000 | $95.60 | $2.4M | 941,662 −2.6% of holding | |
| Quinlan Paul T 5 fills | General Counsel | Sell 10b5-1 | 9,000 | $78.53 | $706.7K | 38,595 −18.9% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.